Safety and efficacy of sacubitril/valsartan in patient with heart failure

• At: Glasgow (Scotland) (2018)
• Type: Poster
• Poster code: POS-HPS-048
• By: RAY, Chin (Chang Gung Memorial Hospital, Linkou, Taiwan, Department of Pharmacy)
• Co-author(s): Chin-Ying Ray
  Tzu-Cheng Tsai
  Shin-Tarng Deng
  
• Abstract:

  Background

  Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization and high mortality rate within 5 years.According to the PARADIGM-HF study, sacubitril/valsartan (Entresto) reduce cardiovascular risk by 20%. However, clinicians are still worried whether this medicine will cause..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login